Dr. Stephens on Pivotal Data From ELEVATE-RR Trial in Previously Treated CLL

In Partnership With:

Partner | Cancer Centers | <b>Huntsman Cancer Institute at the University of Utah </b>

Deborah M. Stephens, DO, discusses the phase 3 ELEVATE-RR trial comparing the safety and efficacy of acalabrutinib with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Deborah M. Stephens, DO, director of the CLL and Lymphoma Program, Huntsman Cancer Institute, discusses the phase 3 ELEVATE-RR trial (NCT02477696) comparing the safety and efficacy of acalabrutinib (Calquence) with ibrutinib (Imbruvica) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). 

    Results from the study showed no difference in efficacy between the 2 agents with regard to progression-free survival, according to Stephens. However, acalabrutinib showed a more favorable toxicity profile compared with ibrutinib in these patients, Stephens adds.

    Acalabrutinib is a feasible option for this population, and its favorable toxicity profile may result in increased utilization of the agent, Stephens concludes.


    x